Per Novavax:
GAITHERSBURG, Md., Jan. 31, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a request to the U.S Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for immunization of individuals 18 year of age and older against SARS-CoV-2.
The Novavax vaccine would be the first protein-based alternative available in Israel
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company based in Gaithersburg dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Israel’s Ministry of Health today announced an agreement for the purchase of NVX-CoV2373, the company’s recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant.
Immunocore is a commercial-stage biotechnology company based in England with its U.S. headquarters in Rockville, pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease.
Yesterday, Immunocore announced the FDA approval of KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye. Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare, and up to 50% of people with uveal melanoma will eventually develop metastatic disease. Unresectable or metastatic uveal melanoma typically has a poor prognosis and had no approved treatment until KIMMTRAK.
QIAGEN, a Netherlands-based holding company with its U.S. headquarters in Germantown, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Earlier this week Qiagen announced that it had completed a U.S. federal contract to equip local public health authorities with QIAcuity digital PCR system for COVID-19 surveillance.
Full press release ebelow:
Enviva is the world’s largest producer of industrial wood pellets, which are used an energy source used to generate electricity and heat. The company was founded in 2004 and was first located in Richmond, Virginia before moving to Bethesda in 2011.
On Wednesday the company announced a memorandum of understanding (MOU) with its first U.S.-based customer, detailing plans to significantly accelerate its capital expansion timeline due to recent commercial momentum with power and heat generators and with industrials in hard-to-abate sectors. The business update also included preliminary 2021 financial results.
UKidney™ procedure data published in the American Journal of Transplantation; the first such data published in a peer-reviewed journal
UHeart™ recipient patient reaches a two-week milestone post-transplant
You’ve likely seen cranes and construction the last few months next to Lifetime Fitness in Gaithersburg. The construction is for The Carnegie at Washingtonian, a Kisco Senior Living Center, that will feature a seven-story complex with 302 one and two bedroom floorpans for independent living and memory care residences.
The groundbreaking of The Carnegie at Washingtonian Center was last October, but the work has been more visible as of late. Situated on 8.5 acres beside RIO Lakefront at Washingtonian Center, The Carnegie is set to welcome residents in the spring of 2024.
Alex Perdikis, principal owner of Koons Lincoln of Silver Spring, announced the expansion of his dealership holdings into downtown Bethesda with Koons Lincoln of Bethesda last month. The new dealership, housed in a multi-million-dollar state-of-the art facility will showcase Lincoln’s luxury line of SUVs in the heart of Bethesda’s newly revitalized commercial and residential district.
Slated to open in early 2022, the dealership, located at 7315 Wisconsin Avenue in Bethesda, will feature Lincoln Navigators, Aviators, and other models in an innovative street level storefront. In addition, vehicles will be showcased to the public in an elegantly illuminated glass runway. Designed to evoke a glass display case, the runway provides ample space for shoppers to browse Lincoln models and is an exciting exterior focal point of the Lincoln Boutique store. The dealership, designed by Bethesda-based Penney Design Group, will entice shoppers with additional amenities including a spacious modern lounge, coffee bar, private sales suites and more.
The Bethesda-based Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) is a global nonprofit that administers more than $500 million in medical research funds annually. For nearly 40 years, HJF has partnered with researchers and clinicians to provide bench to bedside to battlefield research support.
Today, HJF announced it received nearly $2M to support a study to evaluate treatment for volumetric muscle loss.
Bethesda’s Mytonomy, a leader in enterprise cloud solutions for video-based patient engagement, experience, and healthcare microlearning education, is launching its own channel on the Roku® platform.
In a press release from Thursday, January 13th, Mytonomy stated that it would be making it easy for healthcare systems to close gaps in care and transition patients from hospital to home through its streaming app available on the Roku platform.
Elpiscience is a Shanghai, China and Germantown, MD-based clinical stage biopharmaceutical company focused on innovating and developing next-generation immunotherapy to benefit cancer patients worldwide. This morning Elpiscience announced that its first patient was does in the US Phase I clinical trial of Anti-CD39 monoclonal antibody ES002 for treatment of advanced solid tumors.
Earlier this month, Dr. John Craighead was announced as chief financial officer effective on Jan. 4th 2022. Craighead will lead all finance and corporate development functions for the company.